M. Averna Et Al. , "Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force," ATHEROSCLEROSIS , vol.325, pp.99-109, 2021
Averna, M. Et Al. 2021. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. ATHEROSCLEROSIS , vol.325 , 99-109.
Averna, M., Banach, M., Bruckert, E., Drexel, H., Farnier, M., Gaita, D., ... Magni, P.(2021). Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. ATHEROSCLEROSIS , vol.325, 99-109.
Averna, Maurizio Et Al. "Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force," ATHEROSCLEROSIS , vol.325, 99-109, 2021
Averna, Maurizio Et Al. "Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force." ATHEROSCLEROSIS , vol.325, pp.99-109, 2021
Averna, M. Et Al. (2021) . "Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force." ATHEROSCLEROSIS , vol.325, pp.99-109.
@article{article, author={Maurizio Averna Et Al. }, title={Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force}, journal={ATHEROSCLEROSIS}, year=2021, pages={99-109} }